Oncology Institute (TOI) AI Stock Analysis

• Market Cap: $437.60M
• Dividend Yield: N/A
• Average Volume (3M): 1.97M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.17
• Revenue Growth: 17.53%
• EPS Growth: 14.49%
• Country: US
• Employees: 825
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): -0.15
• Shares Outstanding: 93,504,770
• 10 Day Avg. Volume: 2,441,013
• 30 Day Avg. Volume: 1,966,835
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.60
• Enterprise Value/Revenue: 0.62
• Enterprise Value/Gross Profit: 4.26
• Enterprise Value/Ebitda: -5.46
• 1Y Price Target: $7.00
• Price Target Upside: 48.94% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 56 Neutral
• Price Target: $4.50 ▼(-4.26% Downside)

The Oncology Institute's stock score is primarily impacted by its financial instability and weak valuation. However, strong technical momentum and positive earnings call guidance provide some optimism. The company needs to address profitability and leverage issues to improve its financial health.

Positive Factors

Revenue Growth

Strong revenue growth indicates expanding market presence and successful business strategies, which can enhance long-term financial stability.

Capitated Contract Expansion

Expanding capitated contracts enhances recurring revenue streams and strengthens market position, supporting sustainable growth.

Pharmacy Business Growth

Robust pharmacy growth reflects effective diversification and operational execution, contributing to revenue resilience and competitive advantage.

Negative Factors

High Leverage

High leverage poses risks to financial stability and limits strategic flexibility, potentially impacting long-term growth and investment capacity.

Negative Cash Flow

Negative cash flow indicates liquidity challenges, which can constrain operations and investment in growth opportunities, affecting future performance.

Profitability Challenges

Ongoing profitability issues highlight cost management challenges, which can hinder financial health and long-term shareholder value creation.

Oncology Institute Business Overview & Revenue Model

Company Description

The Oncology Institute (TOI) is a leading provider of comprehensive cancer care services, focusing on delivering advanced treatment options and personalized therapies for patients diagnosed with various types of cancer. Operating across multiple locations, TOI offers a range of services including chemotherapy, radiation therapy, immunotherapy, and supportive care, alongside cutting-edge clinical trials and research initiatives. The institute is dedicated to improving patient outcomes through innovative medical practices and a patient-centric approach.

How the Company Makes Money

The Oncology Institute generates revenue primarily through patient services, which include consultations, diagnostic testing, and treatment therapies such as chemotherapy and radiation. A significant portion of their income comes from reimbursement agreements with insurance companies, Medicare, and Medicaid, as they provide care to a diverse patient base. Additionally, TOI may earn revenue through partnerships with pharmaceutical companies for clinical trials, where they receive funding for conducting research studies and offering access to new treatment options. The institute's focus on innovation and research also allows it to apply for grants and funding from various health organizations, further contributing to its earnings.

Oncology Institute Financial Statement Overview

Summary

The Oncology Institute faces significant financial challenges. Despite modest revenue growth, the company struggles with profitability, high leverage, and negative equity, indicating financial instability. Cash flow issues further exacerbate the situation, posing liquidity risks.

Income Statement

The Oncology Institute shows a modest revenue growth rate of 5.27% TTM, indicating some positive momentum. However, the company struggles with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin is relatively low at 14.60% TTM, reflecting challenges in cost management. Overall, while revenue is growing, profitability remains a significant concern.

Balance Sheet

The balance sheet reveals high leverage with a negative debt-to-equity ratio TTM, indicating financial instability. The negative return on equity suggests that the company is not generating returns for shareholders. The equity ratio is not provided, but the overall high debt levels and negative equity are concerning for financial health.

Cash Flow

Cash flow analysis shows negative operating and free cash flows TTM, with a significant decline in free cash flow growth. The free cash flow to net income ratio is positive, suggesting some efficiency in converting net income to cash, but overall cash flow performance is weak, posing liquidity risks.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	424.38M	393.41M	324.24M	252.48M	203.00M	187.51M
Gross Profit	61.95M	54.00M	59.57M	52.09M	40.85M	36.88M
EBITDA	-48.32M	-50.88M	-70.45M	8.40M	-7.94M	-11.29M
Net Income	-65.89M	-64.66M	-83.07M	152.00K	-10.93M	-14.32M
Balance Sheet
Total Assets	159.80M	172.72M	209.24M	263.75M	203.44M	65.69M
Cash, Cash Equivalents and Short-Term Investments	30.29M	49.67M	82.86M	73.81M	114.30M	6.00M
Total Debt	103.16M	123.15M	119.67M	108.18M	183.00K	11.93M
Total Liabilities	168.78M	169.13M	152.22M	139.07M	99.28M	37.59M
Stockholders Equity	-8.98M	3.59M	57.02M	124.68M	104.16M	28.10M
Cash Flow
Free Cash Flow	-13.07M	-30.33M	-40.88M	-67.28M	-35.73M	-685.88K
Operating Cash Flow	-10.19M	-26.54M	-36.31M	-61.76M	-32.68M	508.24K
Investing Cash Flow	7.24M	46.21M	62.64M	-131.61M	-12.15M	-8.84M
Financing Cash Flow	-3.18M	-3.49M	-6.85M	92.21M	154.01M	11.89M

Oncology Institute Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.70
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TOI, the sentiment is Positive. The current price of 4.7 is above the 20-day moving average (MA) of 4.11, above the 50-day MA of 3.66, and above the 200-day MA of 2.52, indicating a bullish trend. The MACD of 0.30 indicates Negative momentum. The RSI at 71.79 is Negative, neither overbought nor oversold. The STOCH value of 84.69 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TOI.

Oncology Institute Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CYH	―	$583.17M	1.74	―	―	0.74%	―
TALK	―	$463.88M	170.99	2.52%	―	17.43%	―
TOI	―	$437.60M	―	-535.24%	―	17.53%	14.49%
EHAB	―	$430.87M	―	-21.72%	―	-0.39%	-1408.40%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CCRN	―	$397.05M	-46.81	-1.96%	―	-24.30%	-210.27%
AGL	―	$357.90M	―	-60.64%	―	10.12%	-29.12%

Oncology Institute Corporate Events

Oncology Institute’s Earnings Call Highlights Growth and Optimism

The recent earnings call for Oncology Institute, Inc. conveyed an optimistic sentiment, highlighting robust revenue growth and significant expansion in capitated contracts. Despite facing some challenges, such as an adjusted EBITDA loss and a sequential gross margin decline, the company remains confident in its strategic focus on leadership, technology, and pharmacy business growth, which positions it favorably for the future.

The Oncology Institute Reports Strong Q2 2025 Growth

The Oncology Institute, Inc. (TOI) is a leading value-based community oncology group in the United States, providing specialized cancer care and clinical trials across multiple states. In its second quarter of 2025, TOI reported a robust 21.5% increase in revenue compared to the previous year, driven by significant growth in its pharmacy business and the expansion of its value-based care model. The company also announced strategic expansions in Florida and Nevada, which are expected to further enhance its market presence.

Oncology Institute Announces New Board Chairman

On August 8, 2025, Richard Barasch resigned as Chairman of the Board of The Oncology Institute, effective August 12, 2025, with no disagreements cited. Anne McGeorge, with extensive financial and healthcare advisory experience, will succeed him, bringing her strategic guidance to the role. Her appointment is expected to strengthen the company’s leadership and continue its mission of providing exceptional oncology care.

The most recent analyst rating on (TOI) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Oncology Institute stock, see the TOI Stock Forecast page.